Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496677 | 0.86 | SLC6A4 (0.34) | SLC6A4SLC6A2KDM1ASLC6A3 | |
| SCHEMBL4497491 | 0.85 | AKR1C3 (0.38) | SLC6A4ACP1 | |
| SCHEMBL4507517 | 0.83 | ADRB2 (0.34) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4509585 | 0.83 | SMN1; SMN2 (0.37) | IRAK4NPC1RAB9AACP1 | |
| SCHEMBL4505054 | 0.83 | SMYD3 (0.37) | SLC6A4KCNH2NPC1RAB9A | |
| SCHEMBL4493813 | 0.75 | ALDH1A1 (0.37) | SLC6A4SLC6A2 | |
| SCHEMBL4494897 | 0.72 | ACHE (0.43) | MAPK10KCNH2 | |
| SCHEMBL4491405 | 0.68 | KCNN1 (0.41) | KCNH2PTPN1NPC1RAB9A | |
| SCHEMBL7742259 | 0.66 | CSNK1D (0.48) | MAPK10IRAK4CSNK1A1CSNK1DGSK3B | |
| SCHEMBL22955340 | 0.65 | MAPK10 (0.52) | MAPK10HSD17B10NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | MAPK10 1245/4885MCHR1 788/4885SLC6A4 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.